207 related articles for article (PubMed ID: 31236274)
1. Chimeric antigen receptors designed to overcome transforming growth factor-β-mediated repression in the adoptive T-cell therapy of solid tumors.
Hartley J; Abken H
Clin Transl Immunology; 2019; 8(6):e1064. PubMed ID: 31236274
[TBL] [Abstract][Full Text] [Related]
2. CD28-ζ CAR T Cells Resist TGF-β Repression through IL-2 Signaling, Which Can Be Mimicked by an Engineered IL-7 Autocrine Loop.
Golumba-Nagy V; Kuehle J; Hombach AA; Abken H
Mol Ther; 2018 Sep; 26(9):2218-2230. PubMed ID: 30055872
[TBL] [Abstract][Full Text] [Related]
3. TGF-β-responsive CAR-T cells promote anti-tumor immune function.
Hou AJ; Chang ZL; Lorenzini MH; Zah E; Chen YY
Bioeng Transl Med; 2018 May; 3(2):75-86. PubMed ID: 30065964
[TBL] [Abstract][Full Text] [Related]
4. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
[TBL] [Abstract][Full Text] [Related]
5. Secretion of bispecific protein of anti-PD-1 fused with TGF-β trap enhances antitumor efficacy of CAR-T cell therapy.
Chen X; Yang S; Li S; Qu Y; Wang HY; Liu J; Dunn ZS; Cinay GE; MacMullan MA; Hu F; Zhang X; Wang P
Mol Ther Oncolytics; 2021 Jun; 21():144-157. PubMed ID: 33981830
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic adenovirus targeting TGF-β enhances anti-tumor responses of mesothelin-targeted chimeric antigen receptor T cell therapy against breast cancer.
Li Y; Xiao F; Zhang A; Zhang D; Nie W; Xu T; Han B; Seth P; Wang H; Yang Y; Wang L
Cell Immunol; 2020 Feb; 348():104041. PubMed ID: 31983398
[TBL] [Abstract][Full Text] [Related]
7. Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications.
Mirzaei HR; Rodriguez A; Shepphird J; Brown CE; Badie B
Front Immunol; 2017; 8():1850. PubMed ID: 29312333
[TBL] [Abstract][Full Text] [Related]
8. Driving CARs on the Highway to Solid Cancer: Some Considerations on the Adoptive Therapy with CAR T Cells.
Abken H
Hum Gene Ther; 2017 Nov; 28(11):1047-1060. PubMed ID: 28810803
[TBL] [Abstract][Full Text] [Related]
9. Chimeric Antigen Receptor (CAR) Treg: A Promising Approach to Inducing Immunological Tolerance.
Zhang Q; Lu W; Liang CL; Chen Y; Liu H; Qiu F; Dai Z
Front Immunol; 2018; 9():2359. PubMed ID: 30369931
[TBL] [Abstract][Full Text] [Related]
10. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects.
Kagoya Y; Tanaka S; Guo T; Anczurowski M; Wang CH; Saso K; Butler MO; Minden MD; Hirano N
Nat Med; 2018 Mar; 24(3):352-359. PubMed ID: 29400710
[TBL] [Abstract][Full Text] [Related]
11. Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells.
Geyer MB; Brentjens RJ
Cytotherapy; 2016 Nov; 18(11):1393-1409. PubMed ID: 27592405
[TBL] [Abstract][Full Text] [Related]
12. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
Gauthier J; Yakoub-Agha I
Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
[TBL] [Abstract][Full Text] [Related]
13. CAR-T cell therapy in melanoma: A future success story?
Simon B; Uslu U
Exp Dermatol; 2018 Dec; 27(12):1315-1321. PubMed ID: 30288790
[TBL] [Abstract][Full Text] [Related]
14. CAR-Based Strategies beyond T Lymphocytes: Integrative Opportunities for Cancer Adoptive Immunotherapy.
Rotolo R; Leuci V; Donini C; Cykowska A; Gammaitoni L; Medico G; Valabrega G; Aglietta M; Sangiolo D
Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31212634
[TBL] [Abstract][Full Text] [Related]
15. [Prospect for chimeric antigen receptor-engineered T cell immunotherapy for solid tumors].
Zhou SY; Shi YK
Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):490-492. PubMed ID: 30060355
[TBL] [Abstract][Full Text] [Related]
16. Advances and Challenges of CAR T Cells in Clinical Trials.
Holzinger A; Abken H
Recent Results Cancer Res; 2020; 214():93-128. PubMed ID: 31473850
[TBL] [Abstract][Full Text] [Related]
17. Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma.
Chmielewski M; Hombach AA; Abken H
Immunol Rev; 2014 Jan; 257(1):83-90. PubMed ID: 24329791
[TBL] [Abstract][Full Text] [Related]
18. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors.
Li S; Siriwon N; Zhang X; Yang S; Jin T; He F; Kim YJ; Mac J; Lu Z; Wang S; Han X; Wang P
Clin Cancer Res; 2017 Nov; 23(22):6982-6992. PubMed ID: 28912137
[No Abstract] [Full Text] [Related]
19. Optimization of manufacturing conditions for chimeric antigen receptor T cells to favor cells with a central memory phenotype.
Gargett T; Truong N; Ebert LM; Yu W; Brown MP
Cytotherapy; 2019 Jun; 21(6):593-602. PubMed ID: 30975603
[TBL] [Abstract][Full Text] [Related]
20. Chimeric Antigen Receptor (CAR) T-Cell Therapy for Thoracic Malignancies.
Kiesgen S; Chicaybam L; Chintala NK; Adusumilli PS
J Thorac Oncol; 2018 Jan; 13(1):16-26. PubMed ID: 29107016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
